Novartis

Novartis 3Q10

3Q10 Revenues: $12.6 billion (+13%)

3Q10 Earnings: $2.3 billion (+10%)

YTD Revenues: $36.4 billion (+16%)

YTD Earnings: $7.7 billion (+26%)

Comments: Branded pharma sales were up 6% to $7.6 billion in the quarter, while generic sales (the Sandoz unit) posted 18% growth to $2.2 billion and Vaccines/Diagnostics posted $600 million (+21%) in sales. Consumer Health added $1.6 billion (+9%). During the quarter, the company acquired an additional 52% of Alcon, consolidating that company and adding $617 million in sales for the quarter. New and recent launches comprised 20% of net sales ($2.3 billion) in pharma. In the Sandoz unit, biosimilars drove growth; generic Lovenox, launched in the quarter, posted $292 million in revenues.